Silo Wellness Inc.
SILFF
Other OTC0.01
USD
+0.01
- -
ISIN
CA8271242072
Return %
Stock
S&P500
1Y
- -
18.99
3Y
-81.11
64.75
5Y
-92.63
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mike Arnold
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 200 Consumers Road Toronto ON Canada M2J 4R4
- IPO Date
- May 20, 2021
- Website
- silowellness.com
- Similar Companies
- Business
- Silo Wellness Inc. (CSE:SILO, OTCQB:SILFF) operates as a psychedelics and wellness company focused on developing and providing psychedelic therapies and functional mushroom products to support mental health and trauma reduction; core offerings include psilocybin-free functional mushroom tinctures, a psilocybin nasal spray formulation under development in Jamaica, guided psilocybin mushroom retreats in Jamaica and Oregon, psychedelic clinics, and legal functional mushroom consumer products such as tinctures, capsules, topicals, and edibles. The company, founded in 2018 and headquartered at 200 Consumers Road Suite 702 in Toronto, Canada, with foundational operations in Oregon, USA, pursues operations in jurisdictions permitting psychedelic activities including Jamaica for cultivation and retreats, Oregon for licensed services, and targets clients seeking transformative plant medicine experiences through evidence-based, client-autonomous journeys emphasizing safety, preparation, integration, and partnerships with local operators like Go Natural Jamaica. Recent developments encompass a binding letter of intent announced to acquire NUGL Inc. (dba Kaya Jamaica), operator of medical cannabis retail locations and wellness centers in Jamaica, in a transaction valued at CAD $43.3 million via issuance of 2 million treasury shares subject to shareholder approval and CSE halt; a strategic partnership with NUGL/Kaya to integrate psilocybin services into retreats; submission of a CSE listing statement for review of a proposed change of business to Born Defense; and appointment of defense finance leadership signaling diversification beyond psychedelics.
Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business
Silo Wellness Appoints Defense Finance Veteran Richard Craven as CEO to Guide Strategic Transition to Born Defense
Silo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War Doctrine
Silo Wellness Announces Extension of Kaya/NUGL LOI; Annual Filings Delay
Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval